CNA Finance

Menlo Therapeutics Announces Results from a Phase 2 Clinical Trial of Serlopitant for the Treatment of Refractory …
GlobeNewswire (press release)
We are currently enrolling patients in two Phase 3 clinical trials (one in the U.S. and one in Europe) to evaluate serlopitant as a treatment for pruritus associated with prurigo nodularis. Data from each trial is expected in the first half of 2020. We
Menlo Therapeutics' serlopitant comes up short in chronic coughFierceBiotech
Menlo's serlopitant flunks mid-stage cough studySeeking Alpha
Menlo's Drug Fails Again in Clinical Trials, This Time for Chronic CoughXconomy
Endpoints News
all 20 news articles »